

REMARKS

Claims 34, 37, and 39-81 are pending. Independent Claim 34 has been revised to incorporate the limitations of Claim 56 which was indicated as being allowable. Claims 56-62 have been cancelled as redundant. The claims have also been revised to replace the term “gene” with the word “polynucleotide”. Other minor editorial changes have been made to improve the clarity of the claims: Claims 39 and 54 have been revised for clarity. Claims 70, 72 and 73 have been amended to correct dependency. Accordingly, the Applicants do not believe that any new matter has been added.

Claim Objections

Claims 37-39, 45, 49, 54 and 80 were objected to as depending from rejected Claim 34 or for various informalities. This objection is moot in view of the incorporation of the limitations of Claim 38 into Claim 34.

Rejections--35 U.S.C. 112, first paragraph

Claims 34, 36, 40-44, 46-48, 50-53, 55, 63-79 were rejected under 35 U.S.C. 112, first paragraph, as lacking adequate description. These rejections are now moot.

Rejections--35 U.S.C. 112, first paragraph


Claims 34, 36, 40-44, 46-48, 50-53, 55, 63-79 and 81 were rejected under 35 U.S.C. 112, first paragraph, as lacking adequate enablement. This rejection is moot.

CONCLUSION

In view of the above amendments and remarks, the Applicants respectfully submit that this application is now in condition for allowance. Early notification to that effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Thomas M. Cunningham
Attorney of Record
Registration No. 45,394

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)